Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082762 | 0.75 | NPC1 (0.42) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL5218684 | 0.69 | — | — | |
| SCHEMBL1428079 | 0.67 | ALDH1A1 (0.44) | CYP19A1NPC1RAB9AKDM4E | |
| SCHEMBL4658297 | 0.67 | KMO (0.34) | — | |
| Methoxymethane SCHEMBL27908243 | 0.66 | RAB9A (0.50) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL157686 | 0.65 | CYP1A2 (0.32) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL9471509 | 0.65 | CHRM1 (0.39) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL27647008 | 0.65 | CYP1A2 (0.35) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL2070970 | 0.65 | — | — | |
| SCHEMBL28934089 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224174-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2003-09-17 | — | — | EP | claimed |
| EP-0329563-B1 | BENZOCYCLOHEXANE AND BENZOCYCLOHEPTANE DERIVATIVES AND THEIR SALTS, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION, THEIR USE AS MEDICINES AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1993-04-21 | — | — | EP | claimed |
| CN-117561060-A | HDAC6 inhibitors 2-fluoroalkyl-1, 3, 4-oxadiazol-5-yl-thiazoles for the treatment of metabolic disorders and HFPEF | 特纳亚治疗股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117561059-A | HDAC6 inhibitors for the treatment of dilated cardiomyopathy | 特纳亚治疗股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20180250293-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2018-09-06 | — | — | US | disclosed |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2016-10-13 | — | — | US | disclosed |
| US-9296740-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130338157-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8383630-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7777035-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20070043010-A1 | Quinazoline derivatives | ASTRAZENECA UK LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1562596-B1 | DERIVATIVES OF PYRIDINALKYL-AMONOALKYL-1H-INDOLE INHIBITING RECEPTORS 5-HT AND RECAPTURE OF SEROTONIN WHICH CAN BE USED AS ANTIDEPRESSANT AND ANXIOLITIC | MERCK PATENT GMBH (DE) | 2006-08-30 | — | — | EP | disclosed |
| US-20060063811-A1 | PYRIDINALKYL-AMINOALKYL-IH-INDOLE DERIVATIVES HAVING AN INHIBITORY ACTION ON 5-HT AND SEROTONIN REUPTAKE AS ANTIDEPRESSANTS AND ANXIOLYTICS | MERCK PATENT GMBH (DE) | 2006-03-23 | — | — | US | disclosed |
| US-20050209233-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-09-22 | — | — | US | disclosed |
| EP-1562596-A1 | DERIVATIVES OF PYRIDINALKYL-AMONOALKYL-1H-INDOLE INHIBITING RECEPTORS 5-HT AND RECAPTURE OF SEROTONIN WHICH CAN BE USED AS ANTIDEPRESSANT AND ANXIOLITIC | MERCK PATENT GmbH (DE) | 2005-08-17 | — | — | EP | disclosed |
| EP-1448548-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004047840-A1 | DERIVATIVES OF PYRIDINALKYL-AMONOALKYL-1H-INDOLE INHIBITING RECEPTORS 5-HT AND RECAPTURE OF SEROTONIN WHICH CAN BE USED AS ANTIDEPRESSANT AND ANXIOLITIC | MERCK PATENT GMBH (DE) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004041815-A1 | INDOLE DERIVATIVE WITH 5HT1A AFFINITY | MERCK PATENT GMBH (DE) | 2004-05-21 | — | — | WO | disclosed |
| WO-2003042205-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043010-A1 | Quinazoline derivatives | ERBB2, ABL1, EGFR | CYP1A2 749/4885CYP2D6 796/4885CYP19A1 614/4885 |
| US-20180250293-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CYP1A2 1004/4885CYP2D6 2646/4885CYP19A1 3689/4885 |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CYP1A2 1004/4885CYP2D6 2646/4885CYP19A1 3689/4885 |
| US-20050209233-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | NPY5R, NPY1R, NPY2R | CYP1A2 1960/4885CYP2D6 1736/4885CYP19A1 636/4885 |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CYP1A2 1004/4885CYP2D6 2646/4885CYP19A1 3689/4885 |
| US-20060063811-A1 | PYRIDINALKYL-AMINOALKYL-IH-INDOLE DERIVATIVES HAVING AN INHIBITORY ACTION ON 5-HT AND SEROTONIN REUPTAKE AS ANTIDEPRESSANTS AND ANXIOLYTICS | HTR1A, HTR1D, HTR1E | CYP1A2 472/4885CYP2D6 558/4885CYP19A1 1997/4885 |
| US-20130338157-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CYP1A2 1004/4885CYP2D6 2646/4885CYP19A1 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.